Advances in salivary cortisol monitoring for healthcare applications
Kok et al.
The finding, in our words
Salivary cortisol is suitable as an adjunctive measure in decentralised monitoring, with lateral-flow assays providing rapid low-cost discrete measurements and wearable platforms enabling higher-frequency collection but facing biofouling and calibration challenges. Suitability requires validation in authentic saliva against reference methods, not merely low detection limits.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Wearable biochemical monitoring requires a complete measurement chain that integrates quality-controlled biofluid sampling, sensor fusion and metadata capture to convert raw sensor outputs into clinically valid digital biomarkers.
This review establishes that microsampling across blood, saliva, urine and stool matrices offers validated workflows and regulatory recognition for human biomonitoring comparable to conventional methods. It finds that these decentralised approaches enhance participant acceptability and enable screening in remote or low-resource settings.
The review finds that lab-on-chip liquid biopsy technologies are sufficiently mature for distanced cancer screening and follow-up, enabling patient-centric sample collection that reduces exposure risks during pandemics.
Ferrara et al., Biosensors & bioelectronics · source ↗
This review assesses wearable sensors for the continuous biochemical monitoring of body fluids such as sweat, saliva and interstitial fluid, confirming their potential for decentralised healthcare through pilot trials. It emphasises that successful clinical translation depends on large-scale validation and the integration of ethical and sociocultural considerations.
A scoping review of 52 studies found most were high-quality RCTs using CGM, metabolomics and microbiome analysis in endurance athletes, yet evidence linking these biomarkers to performance, recovery or long-term health remains insufficient. This gap between biomarker discovery and clinical validation must be closed before these decentralised tools can guide precision nutrition.